Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Cancer research - 15 Aug 2018

Untch Brian R, Dos Anjos Vanessa, Garcia-Rendueles Maria E R, Knauf Jeffrey A, Krishnamoorthy Gnana P, Saqcena Mahesh, Bhanot Umeshkumar K, Socci Nicholas D, Ho Alan L, Ghossein Ronald, Fagin James A

Abstract excerpt

Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated and anaplastic thyroid cancers (Tpo-Cre/HrasG12V/p53flox/flox ) with the FTI tipifarnib. Treatment caused sustained tumor regression and increased survival; however, early and late...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromogranins

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Neurofibromin 1

Share to Quinolones

Share to Thyroid Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29760048
DOI: 10.1158/0008-5472.CAN-17-1925
PMCID: PMC6095730

Genes

HRAS
EGFR
GNAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.PMID 29760048Read ↗

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.Semantic proximity Read ↗

Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancerSemantic proximity Read ↗

Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.Semantic proximity Read ↗

CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid CancerSemantic proximity Read ↗

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Semantic proximity Read ↗

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.Semantic proximity Read ↗

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.Semantic proximity Read ↗

FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarizationSemantic proximity Read ↗

PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinomaSemantic proximity Read ↗

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.Semantic proximity Read ↗

Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.